These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

769 related articles for article (PubMed ID: 30414798)

  • 1. The Pt-Cr everolimus-eluting stent with bioabsorbable polymer in the treatment of patients with acute coronary syndromes. Results from the SYNERGY ACS registry.
    de la Torre Hernandez JM; Moreno R; Gonzalo N; Rivera R; Linares JA; Veiga Fernandez G; Gomez Menchero A; Garcia Del Blanco B; Hernandez F; Benito Gonzalez T; Subinas A; Escaned J
    Cardiovasc Revasc Med; 2019 Aug; 20(8):705-710. PubMed ID: 30414798
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomized comparison of novel bioresorbable polymer sirolimus-eluting stent and durable polymer everolimus-eluting stent in patients with acute coronary syndromes: The CENTURY II high risk ACS substudy.
    Jiménez VA; Iñiguez A; Baz JA; Valdés M; Ortiz A; Vuilliomenet A; Mainar V; Dudek D; Banai S; Tüller D; Bonnet JL; De Miguel A; Bastos G; Wijns W; Saito S
    Cardiovasc Revasc Med; 2016 Sep; 17(6):355-61. PubMed ID: 27156201
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Titanium-Nitride-Oxide-Coated Versus Everolimus-Eluting Stents in Acute Coronary Syndrome: The Randomized TIDES-ACS Trial.
    Tonino PAL; Pijls NHJ; Collet C; Nammas W; Van der Heyden J; Romppanen H; Kervinen K; Airaksinen JKE; Sia J; Lalmand J; Frambach P; Penaranda AS; De Bruyne B; Karjalainen PP;
    JACC Cardiovasc Interv; 2020 Jul; 13(14):1697-1705. PubMed ID: 32703593
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Subgroup Analysis Comparing Ultrathin, Bioresorbable Polymer Sirolimus-Eluting Stents Versus Thin, Durable Polymer Everolimus-Eluting Stents in Acute Coronary Syndrome Patients.
    Roguin A; Kandzari DE; Marcusohn E; Koolen JJ; Doros G; Massaro JM; Garcia-Garcia HM; Bennett J; Gharib EG; Cutlip DE; Waksman R
    Circ Cardiovasc Interv; 2018 Oct; 11(10):e007331. PubMed ID: 30354631
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mid- to Long-Term Clinical Outcomes of Patients Treated With the Everolimus-Eluting Bioresorbable Vascular Scaffold: The BVS Expand Registry.
    Felix CM; Fam JM; Diletti R; Ishibashi Y; Karanasos A; Everaert BR; van Mieghem NM; Daemen J; de Jaegere PP; Zijlstra F; Regar ES; Onuma Y; van Geuns RJ
    JACC Cardiovasc Interv; 2016 Aug; 9(16):1652-63. PubMed ID: 27476094
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The BIOFLOW-III Italian Satellite Registry: 18-month results of the Orsiro stent in an all-comer high-risk population.
    Bartorelli AL; Versaci F; Briguori C; Tomai F; Aprigliano G; Poli A; Vigna C; Marinucci L; My L; Masi F; Turturo M
    J Cardiovasc Med (Hagerstown); 2019 Jul; 20(7):464-470. PubMed ID: 30994511
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outcome of everolimus eluting bioabsorbable vascular scaffold (BVS) compared to non BVS drug eluting stent in the management of ST-segment elevation myocardial infarction (STEMI) - A comparative study.
    Chakraborty R; Patra S; Banerjee S; Pande A; Khan A; Mandol PC; Ghosh D; De SK; Das SS; Nag R
    Cardiovasc Revasc Med; 2016; 17(3):151-4. PubMed ID: 26905052
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of an optical coherence tomography guided approach in acute coronary syndromes: A propensity matched analysis from the international FORMIDABLE-CARDIOGROUP IV and USZ registry.
    Iannaccone M; D'Ascenzo F; Frangieh AH; Niccoli G; Ugo F; Boccuzzi G; Bertaina M; Mancone M; Montefusco A; Amabile N; Sardella G; Motreff P; Toutouzas K; Colombo F; Garbo R; Biondi-Zoccai G; Tamburino C; Omedè P; Moretti C; D'amico M; Souteyrand G; Meieir P; Lüscher TF; Gaita F; Templin C
    Catheter Cardiovasc Interv; 2017 Aug; 90(2):E46-E52. PubMed ID: 28029210
    [TBL] [Abstract][Full Text] [Related]  

  • 9. One-year clinical performance of ABSORB bioresorbable vascular scaffold in patients presenting with acute coronary syndromes: Results from the RAI registry.
    Moscarella E; Ielasi A; Varricchio A; Cortese B; Loi B; Tarantini G; Pisano F; Durante A; Pasquetto G; Colombo A; Tumminello G; Moretti L; Calabrò P; Mazzarotto P; Tespili M; Silva Orrego P; Corrado D; Steffenino G;
    Catheter Cardiovasc Interv; 2019 Feb; 93(3):404-410. PubMed ID: 30346080
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Everolimus-Eluting Biodegradable Polymer Versus Everolimus-Eluting Durable Polymer Stent for Coronary Revascularization in Routine Clinical Practice.
    Zanchin C; Ueki Y; Zanchin T; Häner J; Otsuka T; Stortecky S; Koskinas KC; Siontis GCM; Praz F; Moschovitis A; Hunziker L; Valgimigli M; Pilgrim T; Heg D; Windecker S; Räber L
    JACC Cardiovasc Interv; 2019 Sep; 12(17):1665-1675. PubMed ID: 31422088
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical Outcomes Following Implantation of Thin-Strut, Bioabsorbable Polymer-Coated, Everolimus-Eluting SYNERGY Stents.
    Kereiakes DJ; Windecker S; Jobe RL; Mehta SR; Sarembock IJ; Feldman RL; Stein B; Dubois C; Grady T; Saito S; Kimura T; Underwood P; Allocco DJ; Meredith IT
    Circ Cardiovasc Interv; 2019 Sep; 12(9):e008152. PubMed ID: 31451014
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improved safety and reduction in stent thrombosis associated with biodegradable polymer-based biolimus-eluting stents versus durable polymer-based sirolimus-eluting stents in patients with coronary artery disease: final 5-year report of the LEADERS (Limus Eluted From A Durable Versus ERodable Stent Coating) randomized, noninferiority trial.
    Serruys PW; Farooq V; Kalesan B; de Vries T; Buszman P; Linke A; Ischinger T; Klauss V; Eberli F; Wijns W; Morice MC; Di Mario C; Corti R; Antoni D; Sohn HY; Eerdmans P; Rademaker-Havinga T; van Es GA; Meier B; Jüni P; Windecker S
    JACC Cardiovasc Interv; 2013 Aug; 6(8):777-89. PubMed ID: 23968698
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 5-Year Outcome Following Randomized Treatment of All-Comers With Zotarolimus-Eluting Resolute Integrity and Everolimus-Eluting PROMUS Element Coronary Stents: Final Report of the DUTCH PEERS (TWENTE II) Trial.
    Zocca P; Kok MM; Tandjung K; Danse PW; Jessurun GAJ; Hautvast RWM; van Houwelingen KG; Stoel MG; Schramm AR; Tjon Joe Gin RM; de Man FHAF; Hartmann M; Louwerenburg JHW; Linssen GCM; Löwik MM; Doggen CJM; von Birgelen C
    JACC Cardiovasc Interv; 2018 Mar; 11(5):462-469. PubMed ID: 29519378
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Final 3-Year Outcomes of MiStent Biodegradable Polymer Crystalline Sirolimus-Eluting Stent Versus Xience Permanent Polymer Everolimus-Eluting Stent: Insights From the DESSOLVE III All-Comers Randomized Trial.
    Takahashi K; Serruys PW; Kogame N; Buszman P; Lurz P; Jessurun GAJ; Koch KT; Troquay RPT; Hamer BJB; Oude Ophuis T; Milewski KP; Hofma SH; Wykrzykowska JJ; Onuma Y; de Winter RJ; Wijns W
    Circ Cardiovasc Interv; 2020 Jun; 13(6):e008737. PubMed ID: 32466676
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Angiographic and clinical outcomes of patients treated with everolimus-eluting bioresorbable stents in routine clinical practice: Results of the ISAR-ABSORB registry.
    Hoppmann P; Kufner S; Cassese S; Wiebe J; Schneider S; Pinieck S; Scheler L; Bernlochner I; Joner M; Schunkert H; Laugwitz KL; Kastrati A; Byrne RA
    Catheter Cardiovasc Interv; 2016 Apr; 87(5):822-9. PubMed ID: 26708019
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An Upfront Two-Stent Strategy for True Coronary Bifurcation Lesions with A Large Side Branch in Acute Coronary Syndrome: A Two-Year Follow-Up Study.
    Yurtdaş M; Asoğlu R; Özdemir M; Asoğlu E
    Medicina (Kaunas); 2020 Feb; 56(3):. PubMed ID: 32121323
    [No Abstract]   [Full Text] [Related]  

  • 17. Absorb bioresorbable vascular scaffold versus everolimus-eluting metallic stent in ST-segment elevation myocardial infarction: 1-year results of a propensity score matching comparison: the BVS-EXAMINATION Study (bioresorbable vascular scaffold-a clinical evaluation of everolimus eluting coronary stents in the treatment of patients with ST-segment elevation myocardial infarction).
    Brugaletta S; Gori T; Low AF; Tousek P; Pinar E; Gomez-Lara J; Scalone G; Schulz E; Chan MY; Kocka V; Hurtado J; Gomez-Hospital JA; Münzel T; Lee CH; Cequier A; Valdés M; Widimsky P; Serruys PW; Sabaté M
    JACC Cardiovasc Interv; 2015 Jan; 8(1 Pt B):189-197. PubMed ID: 25616924
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early outcome of magnesium bioresorbable scaffold implantation in acute coronary syndrome-the initial report from the Magmaris-ACS registry.
    Wlodarczak A; Lanocha M; Jastrzebski A; Pecherzewski M; Szudrowicz M; Jastrzebski W; Nawrot J; Lesiak M
    Catheter Cardiovasc Interv; 2019 Apr; 93(5):E287-E292. PubMed ID: 30537203
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The EXAMINATION trial (Everolimus-Eluting Stents Versus Bare-Metal Stents in ST-Segment Elevation Myocardial Infarction): 2-year results from a multicenter randomized controlled trial.
    Sabaté M; Brugaletta S; Cequier A; Iñiguez A; Serra A; Hernádez-Antolín R; Mainar V; Valgimigli M; Tespili M; den Heijer P; Bethencourt A; Vázquez N; Backx B; Serruys PW
    JACC Cardiovasc Interv; 2014 Jan; 7(1):64-71. PubMed ID: 24332423
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-Term Clinical Outcomes of Patients Treated With Everolimus-Eluting Bioresorbable Stents in Routine Practice: 2-Year Results of the ISAR-ABSORB Registry.
    Wiebe J; Hoppmann P; Colleran R; Kufner S; Valeskini M; Cassese S; Schneider S; Joner M; Schunkert H; Laugwitz KL; Kastrati A; Byrne RA
    JACC Cardiovasc Interv; 2017 Jun; 10(12):1222-1229. PubMed ID: 28641842
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 39.